Clinical trial
Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis
NCT03109236 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis
- Lead sponsor
- National University Hospital, Singapore
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- August 24, 2017
- Completion date
- December 31, 2023
- Enrollment
- 66 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.